Original ResearchPrognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients
Section snippets
Background
The number of studies using health-related quality of life (HRQoL) assessment has been growing over the last decade. The Food and Drug Administration considers HRQoL to be an end-point for assessing direct clinical benefits for the patient [1], [2], [3]. Moreover, there has been evidence to suggest that assessing baseline HRQoL dimension scores in cancer patients improves the prediction of overall survival (OS) [4], [5], [6], [7], [8], [9]. Quinten et al. carried out a meta-analysis involving
Sample
The IFCT 0501 study design has been previously described [14]. Patients aged 70–89 years with stage IV NSCLC or stage III unsuitable for radical radiation therapy and performance status (PS) ≤2 were eligible for this phase III trial. They were randomly assigned 1:1 to four 28-day cycles of monthly carboplatin plus weekly paclitaxel or five 21-day cycles of single agent vinorelbine or gemcitabine, on days 1 and 8 of each cycle. Patients were stratified by centre, World Health Organization (WHO)
Study population
Between April 2006 and December 2009, 451 patients were enrolled. The number of patients who completed the entire questionnaire at baseline was 361 (80.04%), the number of available questionnaires (i.e. with at least one QoL score that could be calculated) being 421 (93.3%). At baseline, the patients who completed the entire QoL questionnaire and those who did not were found to display similar clinical characteristics (Table 1). The baseline HRQoL scores for each dimension have been presented
Discussion
To our knowledge, this is the first analysis of HRQoL data derived from the EORTC QLQ-C30 questionnaire as prognostic markers of OS in elderly advanced NSCLC patients. Based on our data, the GH dimension score provided significant value in addition to PS, treatment type, smoking status, histology, and both ADL and MMS scores.
This is in line with other studies investigating HRQoL in NSCLC patients [6], [14], [15], [16]. Sloan et al. [12] and Jacot et al. [13] demonstrated that overall HRQoL
Conflict of interest statement
Frédéric Fiteni declares no conflict of interest. Dewi Vernerey declares no conflict of interest. Franck Bonnetain reports grants and personal fees from ROCHE, grants, personal fees and non-financial support from NOVARTIS, personal fees from MERCK SERONO, and personal fees from NESTLE. Fabien Vaylet declares no conflict of interest. Hélène Sennelart declares no conflict of interest. Jean Tredaniel declares no conflict of interest. Denis Moro-Sibilot declares participation to Roche, Eli Lilly,
Funding
Funding was received from Ligue Contre Le Cancer and Intergroupe Francophone de Cancérologie Thoracique.
References (22)
- et al.
Endpoints in cancer clinical trials
J Visc Surg
(2014) - et al.
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer
Eur J Cancer
(2003) - et al.
Quality of life as a predictor of cancer survival among Chinese liver and lung cancer patients
Eur J Cancer
(2007) - et al.
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials
Lancet Oncol
(2009) - et al.
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975
Ann Oncol
(2006) - et al.
Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients
Ann Oncol
(2008) - et al.
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Lancet
(2011) - et al.
Quality-of-life end points in cancer clinical trials: the U.S. food and drug administration perspective
J Natl Cancer Inst Monogr
(1996) - et al.
Food and drug administration requirements for approval of new anticancer drugs
Cancer Treat Rep
(1985) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008
Health Qual Life Outcomes
(2009)
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592
J Clin Oncol
Cited by (40)
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study
2022, European Journal of CancerCitation Excerpt :It is worth noting that the characterisation of symptom clusters often focuses on patient symptoms and seldom incorporates other aspects of HRQoL that cover patients' functioning abilities, which are equally important in managing patients with cancer [15]. HRQoL indicators, such as physical, emotional, social, cognitive and role functioning, have also been shown to be inter-related and to be correlated with various symptom scales (e.g. physical-functioning vs pain), as well as being predictive of survival in cancer clinical trials [13,14]. This reiterates the need to have a more holistic picture of the interrelationships among the various HRQoL indicators, which will better inform our choices on effective patient management strategies.
Clinimetrics: The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire
2022, Journal of PhysiotherapyModifiable factors associated with health-related quality of life among lung cancer survivors following curative intent therapy
2022, Lung CancerCitation Excerpt :Rehabilitation services may also need to be remotely-delivered to overcome barriers in access, uptake, and completion [102], particularly during global viral (e.g., COVID-19) pandemics that require social distancing. Additional novel and important contributions of our study are: 1) inclusion of patients who underwent radio/-ablation therapy for stage I lung cancer, a growing patient population given advances in radio/-ablation techniques and often excluded from studies that examined posttreatment lung cancer survivorship issues; 2) focus on individual functional impairments and symptoms that are potentially modifiable with identified effect sizes that have been suggested to be clinically meaningful in patients with lung cancer [80], met multiple statistical significance thresholds, and therefore should be targeted in interventions to improve the HRQL of lung cancer survivors following curative intent therapy; 3) comorbidities defined individually (and not combined as a total sum), which has important implications in the clinical setting to improve control of specific comorbidities (e.g., OSA); 4) HRQL defined with a highly prognostic measure [55–58]; and 5) being (to the best of our knowledge) among the first study to identify factors that explain most (>50%) of the variance in HRQL, enhancing clinical translation. Despite a thorough list of factors examined, we did not have information on spirituality [103] or stigma [104], important factors associated with HRQL in patients with lung cancer; or disease-/progression-free survival, an important patient-relevant (and clinical) endpoint [105].
Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients
2021, ESMO OpenCitation Excerpt :Social epidemiological studies in the 1980s showed that self-reported health or health-related quality of life (HRQoL) variables have independent prognostic power for survival.6,7 This could also be shown for several groups of patients including cancer patients.8-11 In a review, almost all studies of different cancer types showed a significant relation of HRQoL variables with survival.
Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis
2021, Value in HealthCitation Excerpt :We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement when reporting our study.20 Of the 1724 records screened, 138 studies including 158 127 patients with cancer met the inclusion criteria.21-156 The identification and selection of the studies included in this review is reported in a Preferred Reporting Items for Systematic Reviews and Meta-Analysis flowchart (see Appendix 2 in Supplemental Materials found at https://doi.org/10.1016/j.jval.2020.10.017).
- 1
Shared authorship.